Autoimmune Diseases  >>  Lantus (insulin glargine)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lantus (insulin glargine) / Sanofi
NCT00539396: A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Completed
2
110
US
Technosphere Insulin
Mannkind Corporation
Diabetes Mellitus, Type 1
 
12/05
NCT00883558: Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

Checkmark P2 data- EASD
Jul 2012 - Jul 2012: P2 data- EASD
Completed
2
48
US
Insulin Lispro, Humalog, regular human insulin, Humulin R, recombinant human hyaluronidase PH20, Hylenex, rHuPH20, PH20, Insulin glargine, Lantus
Halozyme Therapeutics
Diabetes Mellitus, Type 1
02/10
04/10
NCT01194245: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

Completed
2
135
US
Insulin lispro, Humalog, recombinant human hyaluronidase PH20, Hylenex, rHuPH20, PH20, Insulin aspart, Insulin glulisine, Apidra, Insulin glargine, Lantus
Halozyme Therapeutics
Diabetes Mellitus, Type 1
08/11
08/11
NCT01658579: Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Completed
2
59
US
HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
Sanofi
Type 1 Diabetes Mellitus
05/13
05/13
NCT01053728: Study of How Single Rising Doses of SAR161271 Are Absorbed and Act in Patients With Type 1 Diabetes Mellitus (T1DM)

Completed
1/2
46
Europe
SAR161271, Insulin glargine HOE901
Sanofi
Type 1 Diabetes Mellitus
05/10
11/10

Download Options